Patent Cap in Drug Pricing Bill Seen as Having Muted Effect
July 25, 2024
By: Ryan Davis
Law360
Axinn partner Ted Mathias was quoted in the Law360 article, "Patent Cap in Drug Pricing Bill Seen as Having Muted Effect."
Click here to access the publication, a subscription is required.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
National Bar Association 100th Annual Convention and Exhibits
Sponsorship
Antitrust
Keeping Pace: Updates in Cartel Enforcement
Webinar
Antitrust
GCR Live: Law Leaders Europe 2025
Speaking Engagement
Antitrust
Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
Webinar
Antitrust
AHLA Annual Meeting 2025
Speaking Engagement
Antitrust
SABA North America Annual Conference 2025
Speaking Engagement
Antitrust
Axinn Recognized by Legal 500 2025 U.S. Guide for Excellence in Antitrust and Litigation
Awards & Recognitions
Axinn Earns Band 1 Recognition in Multiple Categories in 2025 Chambers USA Guide
Awards & Recognitions
Antitrust
United States: Class Actions
Byline Articles
Litigation & Trials
Antitrust 101: Criminal Antitrust Enforcement in U.S. v. US Gypsum Co., 438 US 422 (1978)
Podcast